BioMarin Pharmaceutical Company Profile (NASDAQ:BMRN)

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.22) by $0.01. The company earned $317.50 million during the quarter, compared to the consensus estimate of $311.41 million. BioMarin Pharmaceutical had a negative return on equity of 5.77% and a negative net margin of 15.54%. The firm's revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the company posted ($2.61) EPS. View BioMarin Pharmaceutical's Earnings History.

BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for BioMarin Pharmaceutical.

22 brokerages have issued 1 year target prices for BioMarin Pharmaceutical's stock. Their predictions range from $89.00 to $150.00. On average, they anticipate BioMarin Pharmaceutical's share price to reach $110.80 in the next year. View Analyst Ratings for BioMarin Pharmaceutical.

Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:

• 1. According to Zacks Investment Research, "BioMarin’s orphan disease drugs – Vimizim and Kuvan – are doing well, backed by strong underlying patient demand trends. BioMarin should continue to see growth in both the drugs in 2017, driven by robust patient growth and penetration.  Brineura’s FDA and EU approval was a huge boost. Pipeline development is also on track with significant upcoming pipeline news flow. However, BioMarin has suffered few regulatory setbacks related to its pipeline candidates in the past. Delayed approvals or further development setbacks can have a negative impact on the stock. Also, Naglazyme and Vimzin revenues vary on a quarterly basis primarily due infrequent ordering patterns from some countries. Meanwhile, the stock underperformed the broader industry this year so far. Loss estimates have remained stable ahead of the company’s Q2 earnings result. However, BioMarin has a positive record of earnings surprises in the recent quarters." (7/19/2017)
• 2. Cowen and Company analysts commented, "New data include 52 wk follow-up on all patients at BMN270’s 6e13 vg/kg dose, and." (7/11/2017)
• 3. Wedbush analysts commented, "The Wedbush View: While we see meaningful clinical, regulatory and commercial progress this year, we remain NEUTRAL on BMRN as we believe the stock is relatively expensive as it consistently trades at the top of peers." (5/8/2017)
• 4. Jefferies Group LLC analysts commented, "Narrower 1Q GAAP net loss reflects higher revenue & lower OpEx (non- GAAP income of $35M). Next clinical update includes BMN 270 data at ISTH on 7/8-7/13/17." (5/5/2017)
• 5. J P Morgan Chase & Co analysts commented, "By Lotus Inventory Impacting Margins In Q1, all rev lines came in above expectations. While Med-Surg has been a consistent outperformer of late, CRM upside was another bright spot. The strong growth came against a tough comp. Headline margins were disappointing due to a spate of issues including the Lotus recall (not surprising), Fuse scope losses (somewhat more surprising) and litigation charges (also not surprising). The Lotus and Fuse charges are not expected to recur; excluding these, we view margins as fairly in-line. While the revenue raise positions BSX shares more favorably in our view, we continue to see the potential for risk around Lotus. While we expect strong data at EuroPCR, we wonder if mgmt’s FDA timelines are aggressive as we would think the FDA might ask for meaningful additional clinical work on the new delivery system following the EU recall. We remain positive on BSX’s underlying fundamentals but feel its current P/E valuation is appropriate until Lotus issues are entirely resolved or Symetis closes and sales ramp." (5/1/2017)

Some companies that are related to BioMarin Pharmaceutical include Alexion Pharmaceuticals (ALXN), Abcam Plc (ABC), Anika Therapeutics (ANIK), Myovant Sciences Ltd (MYOV), Syros Pharmaceuticals (SYRS), Sinovac Biotech (SVA), ChemoCentryx (CCXI), Mirna Therapeutics (SYBX), Syndax Pharmaceuticals (SNDX), Strongbridge Biopharma PLC (SBBP), Fortress Biotech (FBIO), Mereo BioPharma Group PLC (MPH), Kadmon Holdings (KDMN), Kamada (KMDA), Vericel Corporation (VCEL), Peregrine Pharmaceuticals (PPHM), MediWound (MDWD) and VIVUS (VVUS).

BioMarin Pharmaceutical's management team includes the folowing people:

• Jean-Jacques Bienaime, Chairman of the Board, Chief Executive Officer
• Daniel Keith Spiegelman, Chief Financial Officer, Executive Vice President
• G. Eric Davis, Executive Vice President, General Counsel, Secretary
• Jeff Robert Ajer, Executive Vice President, Chief Commercial Officer
• Robert A. Baffi Ph.D., Executive Vice President - Technical Operations
• Henry J. Fuchs M.D., Executive Vice President and Chief Medical Officer
• Brian R. Mueller, Group Vice President, Corporate Controller, Chief Accounting Officer
• Richard A. Meier, Lead Independent Director
• Willard H. Dere M.D., Independent Director
• Michael G. Grey, Independent Director

BioMarin Pharmaceutical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Capital Research Global Investors (10.78%), Vanguard Group Inc. (8.19%), Jennison Associates LLC (7.59%), State Street Corp (2.22%), Palo Alto Investors LLC (1.36%) and TIAA CREF Investment Management LLC (1.28%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical.

BioMarin Pharmaceutical's stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Balyasny Asset Management LLC, Marshall Wace North America L.P., Columbus Circle Investors, Westfield Capital Management Co. LP, State Street Corp, Fred Alger Management Inc. and Eaton Vance Management. Company insiders that have sold BioMarin Pharmaceutical stock in the last year include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer and V Bryan Lawlis. View Insider Buying and Selling for BioMarin Pharmaceutical.

BioMarin Pharmaceutical's stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, TIAA CREF Investment Management LLC, USS Investment Management Ltd, Vanguard Group Inc., Manning & Napier Advisors LLC, Teachers Advisors LLC, PDT Partners LLC and Nexthera Capital LP. View Insider Buying and Selling for BioMarin Pharmaceutical.

Shares of BioMarin Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of BioMarin Pharmaceutical stock can currently be purchased for approximately $92.57.